Novo Nordisk faces legal, regulatory and production tests after oral GLP‑1 obesity pill launch

Start-of-year test for Novo Nordisk

Oral GLP‑1 launch spurs legal and regulatory fight

Novo Nordisk is navigating an intense operational and reputational test after launching the first-ever oral GLP‑1 pill for obesity at the start of January. The Danish drugmaker is simultaneously pursuing legal action and managing regulatory scrutiny as it seeks to translate the new product into durable U.S. demand. Management frames 2026 as a “show me” year focused on protecting intellectual property, shoring up supply and sustaining patient uptake for both oral and injectable obesity therapies.

The company sues telehealth provider Hims & Hers for alleged patent infringement related to its obesity pill, signalling a more aggressive posture against what it calls unlawful encroachment on its drug platform. At the same time, U.S. regulators issue a warning to Novo over advertising that the company must correct, adding to pressure around how the new treatment is presented to patients and prescribers. Executives link these actions to a broader push to ensure the oral pill’s market introduction is not undermined by confusing claims or unauthorised competing products.

Operationally, Novo emphasizes ramping production and managing supply chains to meet rising prescription volumes while defending pricing and reimbursement positions in the United States. Company leadership stresses that sustaining demand for the oral GLP‑1 and maintaining access to its established injectable, Wegovy, require coordinated efforts on manufacturing scale‑up, regulatory clarity and legal deterrence against knock‑offs and unapproved compounds.

CEO outlines “show me” priorities

Chief Executive Mike Doustdar lays out a focused agenda that prioritizes cracking down on compounded semaglutide copycats, expanding U.S. prescription volumes and accelerating next‑generation obesity and diabetes treatments. He tells media the company expects both more patients and higher production in 2026 and cites roughly 246,000 patients currently on Wegovy as a base for future growth. He also highlights Medicare coverage and U.S. reimbursement dynamics as critical to long‑term uptake.

Competitive pressures from peers and unregulated substitutes

Novo faces rising competition from rivals such as Eli Lilly, whose pipeline and commercial momentum raise the bar in obesity care, and from a growing market of cheaper, unapproved compounded semaglutide products that dilute pricing and create safety concerns. The combination of legal, regulatory and market pressures frames the company’s push to protect market share and define standards for the rapidly evolving obesity‑treatment landscape.